Health knowledge made personal
Join this community!
› Share page:
Search posts:

Cross-Reactive Neutralizing Human Domain Antibody Against HIV-1

Posted Sep 27 2012 8:00pm

Description of Invention:
The invention describes the first identified anti-HIV human domain antibody (m36), which can potentially be used alone or synergistically with other anti-HIV antibodies and antiretroviral drugs as a therapeutic and/or preventative for HIV infection. It targets an epitope whose exposure is enhanced by binding of the HIV receptor CD4 to the HIV envelope glycoprotein (Env). M36 was identified by sequential panning of a newly developed large human VH library against Envs from different HIV-1 isolates. The antibody can neutralize HIV-1 primary isolates from different clades at low (nM) concentrations and due to its small size (14 kDa) is potentially able to efficiently penetrate lymphoid tissues where the virus replicates. The antibody is fairly well characterized and the inventors are generating derivatives of this antibody to improve the half-life and increase its potency and cross-reactivity.

Treatment and prevention of HIV infections

  • Human monoclonal antibody, thus eliminating some of the issues associated with humanized or murine monoclonal antibodies
  • Potential neutralization of HIV-1 primary isolates from different clades at nM concentrations
  • Relatively small size allows for potential efficient penetration into lymphoid tissues

Development Status:
In vitro data is available

Dimiter S Dimitrov (NCI)
Weizao Chen (NCI)

Patent Status:
HHS, Reference No. E-043-2008/0
PCT, Application No. PCT/US2009/030351 filed 07 Jan 2009
US, Application No. 12/811,998 filed 07 Jul 2010

Relevant Publication:
  1. Zhang MY, et al. [ PMID 15168796 ]
  2. Zhang MY, et al. [ PMID 14659751 ]
  3. Huang CC, et al. [ PMID 16284180 ]
  4. Chen W, et al. [ PMID 18687338 ]
  5. Chen W, et al. [ PMID 18957538 ]
  6. NCI Press Release dated October 20, 2008 — Researchers Identify Novel Type of Antibody that Potently Inhibits HIV Infection [ Press Release ]

Collaborative Research Opportunity:
The National Cancer Institute CCR Nanobiology Program is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize domain antibodies and nanoantibodies against HIV. Please contact John D. Hewes, Ph.D. at 301-435-3121 or for more information.

For Licensing Information Please Contact:
Sally Hu Ph.D., M.B.A.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325 Room 21,
Rockville, MD 20852
United States
Phone: 301-435-5606
Fax: 301-402-0220

Ref No: 1809

Updated: 09/2012

Post a comment
Write a comment:

Related Searches